Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 54 of 180 for:    ERYTHROMYCIN

Intradermal LPS and Antibiotics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03779360
Recruitment Status : Recruiting
First Posted : December 18, 2018
Last Update Posted : December 18, 2018
Sponsor:
Collaborator:
Maruho Co., Ltd.
Information provided by (Responsible Party):
Centre for Human Drug Research, Netherlands

Brief Summary:
Erythromycin and clindamycin are believed to have anti-inflammatory aspects. This study investigates the possible anti-inflammatory effects of erythromycin and clindamycin.

Condition or disease Intervention/treatment Phase
Inflammation; Skin Drug: Erythromycin 4% topical gel formulation: Drug: Clindamycin 1% lotion formulation: Drug: Prednisolone tablet (0.5mg/kg; parallel comparison): Drug: Clobetasol propionate 0.05% topical formulation (crossover comparison): Other: Lipopolysaccharide Not Applicable

Detailed Description:
Convincing mechanistic reports on the immunomodulatory action of erythromycin and clindamycin are scarce, rarely based on experiments in freshly isolated human immune cells, and potentially contradicting. Moreover, direct immunomodulatory effects of both antibiotics have never been demonstrated in vivo. The Centre for Human Drug Research Biomarker lab has studied in depth the immunomodulatory actions of erythromycin and clindamycin in vitro. These in vitro experiments on primary human immune cells demonstrated that both erythromycin and clindamycin are able to modulate the immune response of peripheral blood mononuclear cells upon stimulation with different immune triggers such as lipopolysaccharide (LPS) and polyI:C. In this current study the in vitro work will be translated to an in vivo study where it will be made into an intradermal LPS skin challenge model in healthy volunteers.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Factorial Assignment
Intervention Model Description: An interventional, open-label, comparator controlled study to investigate the immunomodulatory effects of erythromycin and clindamycin in an LPS skin challenge model in healthy volunteers.
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Investigating Anti-inflammatory Effects of Topical Antibiotics in an LPS Skin Challenge Model
Actual Study Start Date : October 12, 2018
Estimated Primary Completion Date : January 31, 2019
Estimated Study Completion Date : January 31, 2019

Arm Intervention/treatment
Active Comparator: Subjects 1-6
7 day treatment of erythromycin and clindamycin twice daily on indicated skin areas prior to Clobetasol treatment; randomized either on the left or right arm for 2 days.
Drug: Erythromycin 4% topical gel formulation:
7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Erythromycin is a bacteriostatic antibiotic that belongs to the macrolide group of antibiotics. Macrolides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical gel formulation with hyprolose and ethanol.

Drug: Clindamycin 1% lotion formulation:
7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Clindamcin is a bacteriostatic antibiotic that belongs to the lincosamide group of antibiotics. Lincosamides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical lotion formulation with ethanol.

Drug: Clobetasol propionate 0.05% topical formulation (crossover comparison):

2 day pre-treatment with clobetasol propionate 0.05% topical formulation applied twice daily on marked area on left or right side of the volar lower arm.

Clobetasol propionate 0.05% topical formulation (crossover comparison):

Clobetasol propionate is a potent synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2.


Experimental: Subjects 7-24
7 day treatment of erythromycin and clindamycin twice daily on indicated skin area prior to 4 Lipopolysaccharide injections and Clobetasol treatment; randomized either on the left or right arm for 2 days.
Drug: Erythromycin 4% topical gel formulation:
7 day pre-treatment with erythromycin and clindamycin applied twice daily on marked area on left (erythromycin) and right side (clindamycin) of the volar lower arm. Erythromycin is a bacteriostatic antibiotic that belongs to the macrolide group of antibiotics. Macrolides act as bacteriostatic by reversibly binding to the P site on the 50S subunit of bacterial ribosomes. A topical gel formulation with hyprolose and ethanol.

Drug: Clobetasol propionate 0.05% topical formulation (crossover comparison):

2 day pre-treatment with clobetasol propionate 0.05% topical formulation applied twice daily on marked area on left or right side of the volar lower arm.

Clobetasol propionate 0.05% topical formulation (crossover comparison):

Clobetasol propionate is a potent synthetic corticosteroid with anti-inflammatory, anti-pruritic, and vasoconstrictive properties. Clobetasol propionate exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators. Specifically, clobetasol propionate appears to induce phospholipase A2 inhibitory proteins, thereby controlling the release of the inflammatory precursor arachidonic acid from membrane phospholipids by phospholipase A2.


Other: Lipopolysaccharide
As TLR4 agonist, purified lipopolysaccharide prepared from Escherichia Coli: 113: H10:K negative (U.S. Standard Reference Endotoxin) will be used. This LPS batch is manufactured in the US by the National Institute of Health (NIH). Subjects will receive two intradermal doses of LPS in each forearm on day 0 (4 LPS injections in total, except for subjects 1-6 who receive none and subjects 25-27 will receive 2 LPS injections, only in the right arm). The dose per injection is 10 ng.
Other Name: LPS

Active Comparator: Subjects 25-30
0.5mg/kg prednisolone two days prior to Lipopolysaccharide injections
Drug: Prednisolone tablet (0.5mg/kg; parallel comparison):
2 day pre-treatment with prednisolone daily dose 0.5mg/kg (0.25mg/kg in the morning and 0.25mg/kg in the evening). Prednisolone tablet (0.5mg/kg; parallel comparison): Prednisolone is a synthetic corticosteroid with predominant glucocorticoid activity and as such it is widely used in the treatment for inflammatory and autoimmune diseases. Prednisolone exerts its effect by binding to cytoplasmic glucocorticoid receptors and subsequently activates glucocorticoid receptor mediated gene expression. This results in synthesis of certain anti-inflammatory proteins, while inhibiting the synthesis of certain inflammatory mediators.

Other: Lipopolysaccharide
As TLR4 agonist, purified lipopolysaccharide prepared from Escherichia Coli: 113: H10:K negative (U.S. Standard Reference Endotoxin) will be used. This LPS batch is manufactured in the US by the National Institute of Health (NIH). Subjects will receive two intradermal doses of LPS in each forearm on day 0 (4 LPS injections in total, except for subjects 1-6 who receive none and subjects 25-27 will receive 2 LPS injections, only in the right arm). The dose per injection is 10 ng.
Other Name: LPS




Primary Outcome Measures :
  1. Change in perfusion by Laser speckle contrast imaging (LSCI) [ Time Frame: Baseline, 3, 6, 10, 24 and 48 hours post LPS injection ]
    Cutaneous microcirculation between pre and post-dose will be assessed using the laser speckle imager.

  2. Change in erythema by Antera 3D camera and 2D camera [ Time Frame: Baseline, 3, 6, 10, 24 and 48 hours post LPS injection ]
    Standardized photographs will be taken using the Antera camera (Antera 3D, Miravex, Ireland).

  3. Change in erythema by clinical evaluation (erythema grading scale) [ Time Frame: Baseline, 3, 6, 10, 24 and 48 hours post LPS injection ]
    At the specific time points pre and post dose the colour of the injected area is scored (erythema index), on a 4 point scale; normal, mild, moderate, severe.

  4. Change in temperature by thermography in celsius [ Time Frame: Baseline, 3, 6, 10, 24 and 48 hours post LPS injection ]
    Skin temperature will be measured using a thermal imaging camera.

  5. Change in skin microbiome [ Time Frame: Baseline, 3, 6, 10, 24 and 48 hours post LPS injection ]

    Collection of skin culture samples is a non-invasive procedure where a sterile polyester flock tip per site is passed along the surface of treated and non-treated areas.

    bacteria studied include but are not limited to: Acinetobacter Anaerococcus Corynebacterium Enhydrobacter Finegoldia Lactobacillus Micrococcus Paracoccus Peptoniphilus Prevotella Propionibacterium Staphylococcus Streptococcus




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy male or female subjects, 18 to 45 years of age, inclusive. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, blood serology and urinalysis;
  2. Body mass index (BMI) between 18 and 30 kg/m2, inclusive, and with a minimum weight of 50 kg;
  3. Fitzpatrick skin type I-III (Caucasian);
  4. Able and willing to give written informed consent and to comply with the study restrictions.
  5. Able to work with the eDiary app.

Exclusion Criteria:

  1. Any disease associated with immune system impairment, including auto-immune diseases, HIV and transplantation patients;
  2. Type 1 or type 2 diabetes mellitus;
  3. Any vaccination within the last 3 months;
  4. Family history of psoriasis;
  5. History of pathological scar formation (keloid, hypertrophic scar);
  6. Have any current and / or recurrent pathologically, clinical significant skin condition at the treatment area (i.e. atopic dermatitis);
  7. Hypersensitivity for dermatological marker at screening;
  8. Requirement of immunosuppressive or immunomodulatory medication within 30 days prior to enrollment or planned to use during the course of the study;
  9. Excessive sun exposure or a tanning booth within 3 weeks of enrollment;
  10. Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year;
  11. Loss or donation of blood over 500 mL within three months prior to screening. Or the donation of plasma within 14 days prior to screening;
  12. Current smoker and/or regular user of other nicotine-containing products (e.g., patches);
  13. History of or current drug or substance abuse considered significant by the PI (or medically qualified designee), including a positive urine drug screen.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03779360


Contacts
Layout table for location contacts
Contact: Thomas Buters, MD +31 71 5246 400 clintrials@chdr.nl

Locations
Layout table for location information
Netherlands
Centre for Human Drug Research Recruiting
Leiden, Zuid-Holland, Netherlands, 2333 CL
Contact: Thomas Buters, MD         
Sponsors and Collaborators
Centre for Human Drug Research, Netherlands
Maruho Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Matthijs Moerland, PhD Researc Director

Layout table for additonal information
Responsible Party: Centre for Human Drug Research, Netherlands
ClinicalTrials.gov Identifier: NCT03779360     History of Changes
Other Study ID Numbers: CHDR1752-B
First Posted: December 18, 2018    Key Record Dates
Last Update Posted: December 18, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Erythromycin
Erythromycin Estolate
Erythromycin Ethylsuccinate
Erythromycin stearate
Dermatitis
Inflammation
Pathologic Processes
Skin Diseases
Anti-Bacterial Agents
Clindamycin
Clindamycin palmitate
Clindamycin phosphate
Antibiotics, Antitubercular
Prednisolone
Methylprednisolone Acetate
Methylprednisolone
Methylprednisolone Hemisuccinate
Prednisolone acetate
Clobetasol
Anti-Inflammatory Agents
Prednisolone hemisuccinate
Prednisolone phosphate
Anti-Infective Agents
Antitubercular Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents